Improving Overall Health

Slides:

Advertisements

Similar presentations

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Advertisements

Diabetic Dyslipidemia in Practice

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

New Data on the Safety of SGLT2 Inhibitors

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on Emerging GLP-1 Receptor Agonists

Updates on CVOT Data and Clinical Comparisons That Matter

Patient Case Discussions in T2D: What Intensification Plan Is Best?

What Comes Second?.

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Updates on Outcomes for Novel T2D Therapies

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Examining CV Effects of Basal Insulin Therapy

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

SGLT2 Inhibitors and CV Outcomes

Emerging CVOT Data and Clinical Application

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

Impacting CV Risk With Diabetes Medications

Clinical Application of New CV Outcomes Data

GLP-1 Receptor Agonists: How Early Is Appropriate?

T2DM and CV Outcomes Trials: A Deep Dive!

A Deep Dive Into CVOTs.

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Translating Atopic Dermatitis

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Case Study Role of DPP-4 Inhibitors

PCSK9 Inhibitors and Cardiovascular Outcomes

Tackling CV Risk in T2DM.

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Early and Intensive T2D Management:

Breaking Down the CVOTs

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Learning Objectives Metabolic Abnormalities Associated With T2D.

Antihyperglycemic Therapy

CV Outcomes and Adherence With GLP-1 RAs

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Oral Combination Therapy for T2D

Updates From ACC.

Optimizing Joint Health in Hemophilia

Patient Selection for Modern T2D Agents

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Getting PPG Under Control

2015 EASD In Review: CV Risk management in t2dm

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

What's New in Oral Combination Therapy for Type 2 Diabetes?

Emerging Advances in Reducing Renal Complications of T2D

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Expert Perspectives.

Glucose-lowering medication in type 2 diabetes: overall approach.

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Presentation transcript:

Improving Overall Health

Glycemic Control and Its Effects on Outcomes

Individualizing T2D Treatment

Lifestyle Management

Decreasing CV Risk in Patients With T2D and Known CV Risk

Glycemic and Extraglycemic Effects of New Therapeutic Classes for T2D

EMPA-REG OUTCOME and What's to Come

GLP-1 Receptor Agonist CVOTs LEADER, SUSTAIN-6, ELIXA

CV Safety of DPP-4 Inhibitors

Clinical Implications of the CVD-REAL Observational Study

Safety of New Therapeutic Agents for T2D

Concluding Remarks

Abbreviations

Abbreviations (cont)